Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

A man who says he got 'Ozempic penis' from the weight loss drug Wegovy has opened up on how his sex life has been going ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

The server encountered an error and could not complete your request. If the problem persists, please contact us using the ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Shares of Novo Nordisk (NYSE:NVO), traded in Copenhagen, rose over 5% on Friday, extending gains from the previous session.

Investing.com - Copenhagen-listed shares of Novo Nordisk (CSE:NOVOb) rose by more than 5% on Friday, extending gains notched in the prior session, after a weight-loss pill from chief rival Eli Lilly ...